Disclosures for "Diplotype-based Expanded Use of Individualized Allele-specific Antisense Oligonucleotides"
-
Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biomarin. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biomarin. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis Precision Medicines. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Illumina. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Illumina . Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Kim Mcmanus has received research support from California Institute for Regenerative Medicine. The institution of Dr. Kim Mcmanus has received research support from National Institutes of Health/NCATS.
-
Mrs. Olsson has nothing to disclose.
-
Mrs. Protopsaltis has nothing to disclose.
-
Prof. Gleeson has received personal compensation for serving as an employee of Ionis. Prof. Gleeson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Stephen Kingsmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Third Rock Ventures. Stephen Kingsmore has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB2 Bio. Stephen Kingsmore has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Illumina. Stephen Kingsmore has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ACMGG. Stephen Kingsmore has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Stephen Kingsmore has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Rady Children's Institute for Genomic Medicine. Stephen Kingsmore has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Sidra Medicine. Stephen Kingsmore has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Stephen Kingsmore has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cold Spring Harbor Press. Stephen Kingsmore has stock in Third Rock Ventures. The institution of Stephen Kingsmore has received research support from Alexion, Amgen, Biomarin, Chiesi, Inozyme, Ionis, Mahzi, Orchard, Sanofi, Rocket, Sarepta, Sentynyl, Travere, Ultragenyx. The institution of Stephen Kingsmore has received research support from NIH. Stephen Kingsmore has received intellectual property interests from a discovery or technology relating to health care. Stephen Kingsmore has received intellectual property interests from a discovery or technology relating to health care.